Please login to the form below

Not currently logged in
Email:
Password:

Merck and Galapagos form partnership

Merck & Co has signed a multi-year global strategic alliance with Belgian drug discovery company Galapagos

Merck & Co has signed a multi-year global strategic alliance with Belgian drug discovery company Galapagos focused on the discovery and pre-clinical development of small-molecule candidate drugs to treat inflammatory diseases.

Under the terms of the agreement, Galapagos will receive an upfront fee of €2.5m. It is also eligible to receive €192m in milestone payments for multiple products based on drug targets, plus potential royalties and sales milestones on any products included in the deal that reach market.

In return, Merck will have the exclusive option to license any compound for clinical development and commercialisation worldwide.

Onno van de Stolpe, CEO of Galapagos said: "This new alliance with Merck in inflammatory diseases, our sixth pharma alliance to date, underscores the quality and versatility of Galapagos' target discovery platform. Galapagos has proven it delivers on its alliance programmes, making us attractive to potential pharma partners seeking to fill their pipelines with medicines based on novel modes of action."

Galapagos, which has no drugs on the market, has forecast €100m in largely partnership-driven revenue this year. Its other major tie-ups are with Eli Lilly, GlaxoSmithKline and Johnson & Johnson's Janssen Pharmaceutica unit.

Merck's deal with Galapagos is the US drugmaker's second this year, following an agreement signed in January, in which the companies elected to collaborate on the development of therapies for diabetes and obesity. 

21st April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics